<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04509791</url>
  </required_header>
  <id_info>
    <org_study_id>S63466</org_study_id>
    <secondary_id>2019-003265-17</secondary_id>
    <nct_id>NCT04509791</nct_id>
  </id_info>
  <brief_title>MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)</brief_title>
  <acronym>Meld-ATG</acronym>
  <official_title>MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II, Multi-centre, randomised, double-blind, placebo-controlled, Multi-arm parallel&#xD;
      cohort trial.&#xD;
&#xD;
        -  to investigate the effect of 2.5 mg/kg og ATG on the preservation of stimulated&#xD;
           C-peptide at 12 months compared to placebo&#xD;
&#xD;
        -  to identify the minimally effective dose of ATG that shows an effect on C-peptide when&#xD;
           compared to placebo at 12 months&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase II, Multi-centre, randomised, double-blind, placebo-controlled, Multi-arm parallel&#xD;
      cohort trial.&#xD;
&#xD;
      Randomisation wil be stratified by age. The trial consist of seven cohorts. The first cohort&#xD;
      of 30 participants will be randomised to placebo, 2.5 mg/kg, 1.5 mg/kg, 0.5 mg/kg and 0.1&#xD;
      mg/kg.&#xD;
&#xD;
      ATG total dose in a 1:1:1:1 allocation ratio. There will be an initial age step down&#xD;
      selection of this cohort with recruitment starting with dose aged 12-25 years and, providing&#xD;
      no new safety concerns are raised in the first 10 participants to receive active dose,&#xD;
      progressing to all ages (5-25 years) The next two cohorts of 12 participants will be&#xD;
      randomised to placebo, 2.5 mg/kg, and 2 specified middle ATG total doses in a 1:1:1:1&#xD;
      allocation ratio.&#xD;
&#xD;
      The next four cohorts of 15 participants will be randomised to placebo, 2.5 mg/kg, and a&#xD;
      single selected middle ATG total doses in a 1:1:1 allocation ratio.&#xD;
&#xD;
      This design allows sequential adjustment of the middle doses to be explored following review&#xD;
      of all safety and early efficacy data by the Independent Data Monitoring Committee ( IDMC)&#xD;
      and Dose Determine Committee (DDC) to seek the minimum effective dose&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 24, 2020</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>the trial design consists of 7 cohorts, each recruited sequentially, with between 3 and 5 treatment arms ( there will be fewer arms for later cohorts)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the area under the stimulated C-peptide response curve</measure>
    <time_frame>over the first 2 hours of a mixed meal tolerance test (MMTT) at 12 months post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the area under the stimulated C-peptide response curve</measure>
    <time_frame>over the first 2 hours of a MMTT at baseline, 3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dry blood spot (DBS) C-peptide measurements</measure>
    <time_frame>at all observation times</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cluster of differentiation 4 (CD4) positive T cells and Cluster of differentiation 8 (CD8) positive T cells</measure>
    <time_frame>over 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>over 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin requirements</measure>
    <time_frame>over 12 months</time_frame>
    <description>The need for insulin (units) on a daily basis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1D-associated autoantibodies (glutamic acid decarboxylase antibodies (GADA), insulin auto-antibodies (IAA), IA-2 antibodies (IA-2A) and Zinc transporter 8 antibodies (ZnT8A))</measure>
    <time_frame>over 12 months</time_frame>
    <description>The presence of T1D-associated autoantibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>continuous glucose monitoring (CGM) measurements ( time in range, time above time below)</measure>
    <time_frame>over 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.5 mg ATG/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the trial consists of 7 cohorts. The first cohort of 30 participants will be randomised to placebo, 2.5 mg/kg, 1.5 mg/kg, 0.5 mg/kg en 0.1 mg/kg in a 1:1:1:1:1 allocation ratio</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.5 mg ATG/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the next two cohorts of 12 participants will be randomised to placebo, 2.5 mg/Kg, and 2 specified middle ATG total doses in a 1:1:1:1 allocation ratio</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5 mg ATG/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The next four cohorts of 15 participants will be randomised to placebo, 2.5 mg/kg and a single selected middle ATG total dose in a 1:1:1 allocation ratio</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.1 mg ATG/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the trial consists of 7 cohorts. The first cohort of 30 participants will be randomised to placebo, 2.5 mg/kg, 1.5 mg/kg, 0.5 mg/kg en 0.1 mg/kg in a 1:1:1:1:1 allocation ratio</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-Human Thymocyte Immunoglobulin, Rabbit</intervention_name>
    <description>MELD - ATG : Minimum effective low dose ant-human thymocyte globulin (rabbit)</description>
    <arm_group_label>0.1 mg ATG/kg</arm_group_label>
    <arm_group_label>0.5 mg ATG/kg</arm_group_label>
    <arm_group_label>1.5 mg ATG/kg</arm_group_label>
    <arm_group_label>2.5 mg ATG/kg</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>ATG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  has given written informed consent to participate; or have a parent or legal guardian&#xD;
             provide written informed consent. Individual under the age of consent will be asked to&#xD;
             assent to trial participation&#xD;
&#xD;
          -  be aged &gt; 5 years to &lt; 25 years at written informed consent/assent&#xD;
&#xD;
          -  have been diagnosed with T1d within 3-9 weeks of planned treatment day 1&#xD;
&#xD;
          -  have random C-peptide levels &gt; 200 pmol/L measured at screening, as tested centrally&#xD;
&#xD;
          -  have 1 or more diabetes-related autoantibody (GADA, IA-2A or ZnT8A) present at&#xD;
             screening, as tested centrally&#xD;
&#xD;
          -  will be &gt; 6 weeks form last live immunisation at planned treatment day 1 and be&#xD;
             willing to forgo live vaccines during the trial until 6 months post treatment&#xD;
&#xD;
          -  be willing to comply with intensive diabetes management&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes&#xD;
&#xD;
          -  Evidence of prior or current tuberculosis (TB) infection&#xD;
&#xD;
          -  Clinically significant abnormal full blood count (FBC), renal function or liver&#xD;
             function at screening&#xD;
&#xD;
          -  Requiring use of other immunosuppressive or immunomodulation agents, including chronic&#xD;
             use of systemic steroids&#xD;
&#xD;
          -  any active chronic infections at screening, or any active acute or chronic infections&#xD;
             at baseline or on treatment day, which would contraindicate any additional&#xD;
             immunosuppression&#xD;
&#xD;
          -  seropositive for human immunodeficiency virus (HIV),hepatitis B of hepatitis C&#xD;
             infection at screening&#xD;
&#xD;
          -  positive for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) based on&#xD;
             local testing regimen&#xD;
&#xD;
          -  unwilling to use appropriate contraception if sexually active during the trial, from&#xD;
             date of written informed consent until completion of the 12-month follow-up visit&#xD;
&#xD;
          -  any history of malignancies, other than skin&#xD;
&#xD;
          -  current or ongoing use of non-insulin pharmaceuticals that effect glycaemic control&#xD;
&#xD;
          -  active participation in another T1D treatment interventional trial in the previous 30&#xD;
             days prior to screening ( excluding treatment with insulin)&#xD;
&#xD;
          -  any prior treatment with ATG, Abatacept or Anti-CD3 monoclonal antibody (Anti-CD3)&#xD;
&#xD;
          -  known allergy to ATG or to similar products&#xD;
&#xD;
          -  any condition, complicating medical issues, or abnormal clinical laboratory results&#xD;
             that the investigator judges may adversely affect trial conduct, cause increased risk&#xD;
             to the participant, or compromise the trial results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>chantal Mathieu, MD,pHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chantal Mathieu, MD,pHD</last_name>
    <phone>+3216346994</phone>
    <email>chantal.mathieu@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lisa Van Ryckeghem, pHD</last_name>
    <phone>+3216342129</phone>
    <email>MELD-ATG@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Silvia Leitgeb</last_name>
      <email>silvia.leitgeb@medunigraz.at</email>
    </contact>
    <investigator>
      <last_name>Thomas Pieber, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Birgit Rami-Merhar</last_name>
      <email>birgit.rami@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Birgit Rami-Merhar, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rie Braspenning</last_name>
      <email>Rie.Braspenning@uza.be</email>
    </contact>
    <investigator>
      <last_name>Christophe De Block, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paola Gallo</last_name>
      <email>paola.gallo@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Philippe Lysy, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair ziekenhuis Brussel</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ursule Van de Velde</last_name>
      <email>Ursule.VandeVelde@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>Bart Keymeulen, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universite Libre de Bruxelles</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aïcha Hamouda</last_name>
      <email>aicha.hamouda@erasme.ulb.ac.be</email>
    </contact>
    <investigator>
      <last_name>Miriam Cnop, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renka Van Heyste</last_name>
      <email>renka.vanheyste@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Natalie Van den Driessche</last_name>
      <email>natalie.vandendriessche@uzleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Chantal Mathieu, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herlev University Hospital</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gowthami Gunapalasingham</last_name>
      <email>gowthami.gunapalasingham.01@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Jesper Johannesen, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helsinki University Hospital Children and Adolescents</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katriina Koski</last_name>
      <email>katriina.koski@helsinki.fi</email>
    </contact>
    <investigator>
      <last_name>Mikael Knip, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hannoversche Kinderheilanstalt Auf der Bult</name>
      <address>
        <city>Hannöver</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karsten Bode</last_name>
      <email>karsten.bode@hka.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Danne, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sabina Martinenghi</last_name>
      <email>martinenghi.sabina@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Emanuele Bosi, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesù</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Annalisa Deodati</last_name>
      <email>annalisa.deodati@opbg.net</email>
    </contact>
    <investigator>
      <last_name>Stefano Cianfarani, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Slaski Uniwersytet Medyczny w Katowicach</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hanna Szczudło</last_name>
      <email>hanna.szczudlo@sum.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Przemyslawa Jarosz-Chobot, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigita Mali</last_name>
      <email>brigita.mali@kclj.si</email>
    </contact>
    <investigator>
      <last_name>Darja Šmigoc Schweiger</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Trust</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emile Hendriks</last_name>
      <email>aejh6@medschl.cam.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Emile Hendriks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Evans, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Slovenia</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 7, 2020</study_first_submitted>
  <study_first_submitted_qc>August 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2020</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

